For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Regulatory context
Regulatory context; not efficacy evidence
No matched controlled clinical study of this exact preparation was verified in this source audit.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Related-compound evidence is contextual only. Commercial names, modifications and routes do not establish clinical equivalence.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
Cortexin: multicenter placebo-controlled stroke study (2014)
272 patients in a multicenter double-blind placebo-controlled trial.
Reported findings. Authors reported functional improvement within complex stroke care.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Abstract lacks numeric effect estimates; clinical setting, background care and the exact preparation limit generalization. No healthy-person cognition benefit established.
Preparation: Source preparation; commercial equivalence unverified. Route: intramuscular
Read original source ↗Editorial review 2026-10-10. Clinician review pending.
Clinical observation
CORNELia: observational combination-treatment report (2023)
801 people aged 30–80 with chronic cerebral ischemia and cognitive impairment; 30-day observations.
Reported findings. Authors reported improved cognitive and depression scores with Cortexin plus Neuromexol.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Combination treatment and observational allocation prevent assigning change to Cortexin alone. Exact supplier identity remains unverified.
Preparation: Source preparation; commercial equivalence unverified. Route: intramuscular
Read original source ↗Editorial review 2026-10-10. Clinician review pending.
Human report
Public Cortexin focus and injection-site inflammation report
One anonymous public firsthand account; identity, preparation and clinical outcome are not independently verified.
Reported findings. Reporter perceived greater calm, focus, learning and sustained attention to tasks.
Nonresponse. Memory wording is ambiguous and is not encoded as definite improvement or deterioration.
Harms. Injection-site inflammation was reported; same-author preceding comment says it resolved within one or two days.
Limits. Preceding comment nmdqtpi and expanded comment nml4wra are one person’s report, not two independent reports. The reporter did not try Cerebrolysin; speculative comparison is not comparative efficacy evidence. Concurrent interventions and systematic clinical assessment unverified. Selection, reporting, placebo and preparation uncertainties remain. This account is not causal proof, a diagnosed outcome, a population response rate or established safety.
Preparation: Named Cortexin injection; mixture composition and supplier equivalence unverified. Route: Injection stated; intramuscular versus subcutaneous unspecified.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.
Human trial
[Cortexin in the comprehensive treatment of neurological complications of type 2 diabetes mellitus. (Results of the DIACORT multicenter randomized clinical trial)].
DIACORT:110 randomized at five Russian centers;109 completed, type2 diabetes with neurological complications.
Reported findings. Add-on group showed greater improvements in cognition, mood and neuropathy measures.
Nonresponse. Both groups improved on some outcomes; some deficits persisted.
Harms. Five adverse events: add-on urticaria, bacterial rhinitis and respiratory symptoms; control gastric pain and respiratory symptoms. Investigators judged them unrelated.
Limits. Open-label, envelope-randomized design limits attribution. Full methods clarify glycine was oral and B vitamins initially intramuscular then oral; compressed abstract wording must not be assigned to every background treatment. Proposed drug-delivery mechanism was not established by this trial.
Preparation: Trial medicinal Cortexin; commercial catalog mixture equivalence unverified. Route: Intramuscular add-on; background diabetes therapy, oral glycine and B vitamins were co-interventions.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.
Human trial
[Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes].
490 ischemic-stroke patients randomized:246 initialIV,244 initialIM.
Reported findings. Authors report IV noninferiority/equivalence to IM for functional recovery.
Nonresponse. MMSE changes4.11 versus3.88 did not differ significantly, p0.249.
Harms. 74 adverse events in60 initialIV participants versus51 events in41 initialIM participants; reported difference nonsignificant. Event types and relatedness unverified.
Limits. Both arms received active Cortexin; opposite-route placebo maintained blinding, not a no-Cortexin control. Route comparison does not establish absolute treatment benefit versus no Cortexin. Accessible abstract only; full methods and disclosures remain unverified.
Preparation: Active medicinal IV-versus-IM Cortexin preparations; manufacturing details and catalog mixture equivalence unverified. Route: Initial IV versus IM with opposite-route placebo; both groups subsequently received IM Cortexin.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.